Pfizer announced today that it will begin shipping INFLECTRA® (infliximab-dyyb) for injection, a biosimilar of REMICADE® (infliximab), to wholesalers in the United States (U.S.) in late November 2016.  INFLECTRA® received FDA approval this past April for the treatment of inflammatory conditions including Crohn’s disease, ulcerative colitis, and rheumatoid arthritis.  According to the announcement, INFLECTRA® will be introduced at a 15% discount to the current wholesaler acquisition cost (WAC) of REMICADE®, not inclusive of discounts to payers, providers, distributors and other purchasing organizations.

Stay tuned to Big Molecule Watch for more breaking news.